18F-FDG PET/CT在眼附属器黏膜相关淋巴组织淋巴瘤诊断与疗效评估中的作用
研究纳入70例接受放疗的眼附属器黏膜相关淋巴组织淋巴瘤患者,治疗前均行18F-FDG PET/CT,回顾性分析PET/CT参数与EBV抗体、疗效、MRI及Ki-67表达的关系。80%(56/70)患者眼眶FDG摄取阳性,肿块型病变摄取率92.0%(46/50)高于非肿块型50.0%(10/20),FDG摄取阳性者完全缓解率70.4%(38/54)高于阴性者30.8%(4/13)。
要点
- 肿块型病变FDG摄取率92.0%(46/50),高于非肿块型50.0%(10/20)(χ2=13.23,p=0.01)。
- 眼眶、结膜、泪腺淋巴瘤SUVmax分别为5.6、2.9、3.7,三部位间差异有统计学意义(F=5.039,p=0.01)。
- FDG摄取阳性者放疗后完全缓解率70.4%(38/54),高于阴性者30.8%(4/13)(χ2=5.43,p=0.02)。
核心结论
- 18F-FDG PET/CT在眼附属器黏膜相关淋巴组织淋巴瘤的诊断和疗效评估中具有一定潜在价值。
研究设计与样本
- 回顾性研究纳入70例接受放疗的眼附属器黏膜相关淋巴组织淋巴瘤患者,治疗前均行18F-FDG PET/CT,回顾分析病历、病理报告、实验室结果和影像特征。
关键影像表现/征象
- 80%(56/70)患者PET/CT显示眼眶FDG摄取阳性。
- 病灶SUVmax中位水平为4.65±3.00(范围1.2-13.5)。
- 肿块型病变FDG摄取率92.0%(46/50),非肿块型病变FDG摄取率50.0%(10/20)(χ2=13.23,p=0.01)。
- 眼眶、结膜、泪腺淋巴瘤SUVmax分别为5.6、2.9、3.7,三部位间差异有统计学意义(F=5.039,p=0.01)。
- 3例(3/70,4.3%)经PET/CT上调分期。
诊断标准与关键数值
- PET/CT显示80%(56/70)患者眼眶FDG摄取阳性。
- 肿块型病变FDG摄取率92.0%(46/50),非肿块型病变FDG摄取率50.0%(10/20)(χ2=13.23,p=0.01)。
- 眼眶、结膜、泪腺淋巴瘤SUVmax分别为5.6、2.9、3.7,三部位间差异有统计学意义(F=5.039,p=0.01)。
- 放疗后完全缓解率:无FDG摄取者30.8%(4/13),有FDG摄取者70.4%(38/54)(χ2=5.43,p=0.02)。
- 高Ki-67评分与FDG摄取阳性相关(χ2=3.916,p=0.048),但SUVmax与Ki-67评分无显著相关(p=0.971)。
临床应用与阅片要点
- 眼附属器黏膜相关淋巴组织淋巴瘤中80%(56/70)显示眼眶FDG摄取,阅片时应注意非肿块型病变仅50.0%(10/20)有FDG摄取。
- 肿块型病变FDG摄取率92.0%(46/50)高于非肿块型50.0%(10/20),SUVmax在眼眶、结膜、泪腺分别为5.6、2.9、3.7。
- FDG摄取阳性者放疗后完全缓解率70.4%(38/54),高于无FDG摄取者30.8%(4/13)。
- 3例(3/70,4.3%)经PET/CT上调分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study is to evaluate the value of fluorine-18-fludeoxyglucose positron emission tomography (18F-FDG PET)/CT in the diagnosis and treatment evaluation of ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma.
METHODS: 70 patients with OAML who received radiotherapy were recruited in our study. All the patients had the 18F-FDG PET/CT examination before the treatment. We retrospectively reviewed the medical records, pathological reports, laboratory results, and imaging features of all patients. The associations between 18F-FDG PET/CT parameters and Epstein-Barr virus antibodies, treatment response, MRI data, and Ki-67 expression were investigated.
RESULTS: The PET/CT scan indicated that 80% (56/70) of the patients showed orbital FDG avidity. The median level of maximum standardized uptake value (SUVmax) of the lesions was 4.65 ± 3.00 (range:1.2-13.5). 92.0% (46/50) of the mass-forming lesions showed 18F-FDG avidity, while only 50.0% (10/20) of the non-massive lesions had 18F-FDG avidity (χ2 = 13.23, p=0.01). The SUVmax in orbit, conjunctiva, and lacrimal gland lymphoma were 5.6, 2.9, and 3.7, respectively. A significant difference was identified of SUVmax among the three locations' lymphoma using one-way ANOVA analysis (F = 5.039, p = 0.01). After completion of radiotherapy, the complete remission rate was achieved in 30.8% (4/13) of the patients without 18F-FDG avidity, and 70.4% (38/54) in cases with 18F-FDG avidity (χ2 = 5.43, p = 0.02). The correlation between high Ki-67 score and 18F-FDG avidity was confirmed (χ2 = 3.916, p = 0.048); however, no significant correlation was found between the SUVmax and Ki-67 score of the lesions (p = 0.971). Three patients (3/70, 4.3%) were upregulated the stage via PET/CT.
CONCLUSION: 18F-FDG PET/CT had some potential values in the diagnosis and assessment of treatment response in patients with OAML.
ADVANCES IN KNOWLEDGE: The value of 18F-FDG PET/CT for patients with OAML.
引用
- Wang, Ni, Tang, et al. The role of 18F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma. Br J Radiol. 2021. PMID: 34919440. doi:10.1259/bjr.20210635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。